Health and wellness products company USANA Health Sciences (NYSE: USNA) will be reporting earnings this Tuesday after market close. Here’s what investors should know.
USANA missed analysts’ revenue expectations last quarter, reporting revenues of $223.3 million, down 5.3% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ EBITDA estimates but a significant miss of analysts’ EPS estimates.
Is USANA a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting USANA’s revenue to grow 1.8% year on year, slowing from the 6.7% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. USANA has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at USANA’s peers in the consumer staples segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Medifast’s revenues decreased 19.4% year on year, beating analysts’ expectations by 1%, and Vita Coco reported revenues up 33.7%, topping estimates by 6.1%. Medifast traded up 5.2% following the results while Vita Coco was down 11%.
Read our full analysis of Medifast’s results here and Vita Coco’s results here.
There has been positive sentiment among investors in the consumer staples segment, with share prices up 6.3% on average over the last month. USANA is down 3.6% during the same time and is heading into earnings with an average analyst price target of $25 (compared to the current share price of $14.32).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
